Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
Rhea-AI Summary
Mesoblast (Nasdaq:MESO) drew down US$75 million from a new five-year credit facility provided by director and shareholder Dr Gregory George and repaid its senior secured loan to Oaktree and part of a NovaQuest subordinated royalty facility on Dec 29, 2025.
Mesoblast may draw an additional US$50 million until June 30, 2026. The facility carries a fixed 8.00% annual rate, a five-year interest-only period, is initially unsecured until NovaQuest debt is repaid (no later than July 8, 2026), and thereafter will be secured solely by the Temcell royalty. Facility terms include no prepayment or exit fees, no encumbrance of material assets or IP, and 5-year warrants for ~323,000 ADS at US$21.51 per ADS subject to shareholder approval.
Positive
- Initial draw of US$75 million completed
- Facility fixed interest rate of 8.00% per annum
- Optional additional US$50 million available until June 30, 2026
- No prepayment or exit fees and no encumbrance of material assets or IP
Negative
- Initial facility unsecured until NovaQuest debt repaid by July 8, 2026
- Issuance of 5-year warrants for ~323,000 ADS at US$21.51 may dilute shareholders if exercised
News Market Reaction – MESO
In the Dec 30 session, MESO declined 2.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Clinical meta-analysis | Positive | -1.8% | Meta-analysis showed remestemcel-L superior to ruxolitinib in SR-aGvHD outcomes. |
| Dec 03 | Conference participation | Neutral | +2.2% | Participation and fireside chat at Piper Sandler healthcare conference in New York. |
| Nov 24 | Trading update | Positive | +1.6% | AGM trading update highlighting >37% quarterly growth in Ryoncil gross revenue. |
| Nov 20 | Pivotal trial launch | Positive | -3.6% | Planned pivotal Phase 3 trial of Ryoncil plus ruxolitinib in severe SR-aGvHD. |
| Nov 17 | CFO appointment | Neutral | +2.2% | Appointment of James M. O’Brien as US-based CFO to support commercialization. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent MESO news often showed price moves that diverged from generally positive or neutral announcements.
Over the last few months, Mesoblast issued multiple updates, including positive clinical data on remestemcel-L, a pivotal trial initiation for Ryoncil® in SR-aGvHD, and a trading update highlighting expected Ryoncil gross revenue of more than US$30.0 million for the quarter ending Dec 31, 2025. Corporate developments included CFO appointment and conference participation. Despite several constructive milestones, share reactions have been mixed, with frequent divergences between news tone and subsequent price moves. Today’s lower-cost, non-dilutive credit line fits into this ongoing capital and commercialization build-out.
Key Terms
senior secured loan financial
subordinated royalty facility financial
credit-line financial
royalty financial
warrants financial
ads financial
vwap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mesoblast has option to draw down up to US
New facility does not encumber any of Mesoblast's material assets or intellectual property
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has repaid in full its existing senior secured loan from Oaktree Capital Management, Inc. and in part its subordinated royalty facility from NovaQuest Capital Management LLC by drawing down US
The new credit-line has a fixed interest rate of
The new facility has a substantially lower overall cost compared with existing facilities, can be repaid at any time without incurring early prepayment or make-whole fees, does not include exit fees, does not encumber any of Mesoblast's material assets or intellectual property, and has no restrictions on additional unsecured debt or licensing activities. Dr. George will receive 5-year warrants to purchase approximately 323,000 American Depositary Shares (ADSs) at US
Mesoblast Chief Executive Dr. Silviu Itescu said "We greatly appreciate the support of our largest shareholder who provided the most commercially compelling facility in a competitive process run over the course of this year. This facility substantially lowers the company’s cost of capital and frees up all of our major assets to provide total flexibility for strategic partnerships and commercialization."
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast
References / Footnotes
- TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd.
- Based on USD-AUD 0.6722 spot rate published by RBA at Dec 29, 2025
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Allison Worldwide | BlueDot Media |
| Emma Neal | Steve Dabkowski |
| T: +1 603 545 4843 | T: +61 419 880 486 |
| E: emma.neal@allisonworldwide.com | E: steve@bluedot.net.au |
